South Texas Accelerated Research Therapeutics

Recent papers from South Texas Accelerated Research Therapeutics

1. A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal CancersCancer Research Communications · 2026
2. 3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)The Oncologist · 2026
3. 16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer ImmunotherapyThe Oncologist · 2026
4. Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinomaJournal for ImmunoTherapy of Cancer · 2026
5. Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialNature Medicine · 2026
6. Targeting of Wnt–β-Catenin Pathway in Recurrent AmeloblastomaNew England Journal of Medicine · 2026
7. A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 ⁺ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.Journal of Clinical Oncology · 2026
8. Cohort expansion of a phase I study of PLN-101095, a first-in-class dual α v β ₈ /α v β ₁ integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI).Journal of Clinical Oncology · 2026
9. A phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors.Journal of Clinical Oncology · 2026
10. RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a costimulatory bispecific antibody for the treatment of advanced bladder cancer and other Nectin-4–positive solid tumors.Journal of Clinical Oncology · 2026
11. A phase 1/2 dose-escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
12. ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors.Journal of Clinical Oncology · 2026
13. BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
14. SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies.Journal of Clinical Oncology · 2026
15. KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors.Journal of Clinical Oncology · 2026
16. TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2026
17. Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors.Journal of Clinical Oncology · 2026
18. Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.Journal of Clinical Oncology · 2026
19. First-line NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma and pre-existing diabetes: NAPOLI 3 post hoc analysis.Journal of Clinical Oncology · 2026
20. Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.Journal of Clinical Oncology · 2026